运动障碍门诊中的氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）与分子脑成像 - Suppr

Suppr

超能文献

FDG-PET and molecular brain imaging in the movement disorders clinic.

作者信息

Bohnen Nicolaas I, Minoshima Satoshi

出版信息

Neurology. 2012 Sep 25;79(13):1306-7. doi: 10.1212/WNL.0b013e31826c1be1. Epub 2012 Aug 22.

DOI:10.1212/WNL.0b013e31826c1be1

PMID:22914830

Abstract

摘要

相似文献

FDG-PET and molecular brain imaging in the movement disorders clinic.

Neurology. 2012 Sep 25;79(13):1306-7. doi: 10.1212/WNL.0b013e31826c1be1. Epub 2012 Aug 22.

Extrapyramidal syndromes: PET and SPECT.

Neuroimaging Clin N Am. 2010 Feb;20(1):57-68. doi: 10.1016/j.nic.2009.08.017.

[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.

Neurology. 2012 Sep 25;79(13):1314-22. doi: 10.1212/WNL.0b013e31826c1b0a. Epub 2012 Aug 22.

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field.

Ann Neurol. 2021 Nov;90(5):711-719. doi: 10.1002/ana.26187. Epub 2021 Aug 27.

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.

J Nucl Med. 2015 Feb;56(2):234-42. doi: 10.2967/jnumed.114.148619. Epub 2015 Jan 15.

Positron Emission Tomography and Single-Photon Emission Computed Tomography in Neurology.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1636-1654. doi: 10.1212/CON.0000000000000389.

IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.

Nuklearmedizin. 2010;49(4):139-47. doi: 10.3413/nukmed-0290. Epub 2010 May 26.

[Functional imaging in movement disorders].

Neurol Neurochir Pol. 2006 Jan-Feb;40(1):42-50.

[Neuroimaging in dementia].

Presse Med. 2007 Oct;36(10 Pt 2):1453-63. doi: 10.1016/j.lpm.2007.04.029. Epub 2007 Jul 3.

PET and SPECT in brain tumors and epilepsy.

Neurosurg Clin N Am. 2011 Apr;22(2):169-84, viii. doi: 10.1016/j.nec.2010.12.003.

引用本文的文献

Metabolic assessment of cerebral palsy with normal clinical MRI using F-FDG PET imaging: A preliminary report.

Front Neurol. 2022 Sep 15;13:844911. doi: 10.3389/fneur.2022.844911. eCollection 2022.

Clinical Relevance of [F]Florbetaben and [F]FDG PET/CT Imaging on the Management of Patients with Dementia.

Molecules. 2021 Feb 26;26(5):1282. doi: 10.3390/molecules26051282.

Recent Advances in Zirconium-89 Chelator Development.

Molecules. 2018 Mar 12;23(3):638. doi: 10.3390/molecules23030638.

Glucose metabolism measured by positron emission tomography is reduced in patients with white matter presumably ischemic lesions.

Med Sci Monit. 2014 Aug 27;20:1525-30. doi: 10.12659/MSM.892137.

Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.

PLoS One. 2013 Jul 23;8(7):e69190. doi: 10.1371/journal.pone.0069190. Print 2013.

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Alzheimers Dement. 2013 Jan;9(1):e-1-16. doi: 10.1016/j.jalz.2013.01.002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

FDG-PET and molecular brain imaging in the movement disorders clinic.

作者信息

Bohnen Nicolaas I, Minoshima Satoshi

出版信息

Neurology. 2012 Sep 25;79(13):1306-7. doi: 10.1212/WNL.0b013e31826c1be1. Epub 2012 Aug 22.

DOI:10.1212/WNL.0b013e31826c1be1

PMID:22914830

Abstract

摘要

相似文献

FDG-PET and molecular brain imaging in the movement disorders clinic.

Neurology. 2012 Sep 25;79(13):1306-7. doi: 10.1212/WNL.0b013e31826c1be1. Epub 2012 Aug 22.

Extrapyramidal syndromes: PET and SPECT.

Neuroimaging Clin N Am. 2010 Feb;20(1):57-68. doi: 10.1016/j.nic.2009.08.017.

[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.

Neurology. 2012 Sep 25;79(13):1314-22. doi: 10.1212/WNL.0b013e31826c1b0a. Epub 2012 Aug 22.

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field.

Ann Neurol. 2021 Nov;90(5):711-719. doi: 10.1002/ana.26187. Epub 2021 Aug 27.

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.

J Nucl Med. 2015 Feb;56(2):234-42. doi: 10.2967/jnumed.114.148619. Epub 2015 Jan 15.

Positron Emission Tomography and Single-Photon Emission Computed Tomography in Neurology.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1636-1654. doi: 10.1212/CON.0000000000000389.

IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.

Nuklearmedizin. 2010;49(4):139-47. doi: 10.3413/nukmed-0290. Epub 2010 May 26.

[Functional imaging in movement disorders].

Neurol Neurochir Pol. 2006 Jan-Feb;40(1):42-50.

[Neuroimaging in dementia].

Presse Med. 2007 Oct;36(10 Pt 2):1453-63. doi: 10.1016/j.lpm.2007.04.029. Epub 2007 Jul 3.

PET and SPECT in brain tumors and epilepsy.

Neurosurg Clin N Am. 2011 Apr;22(2):169-84, viii. doi: 10.1016/j.nec.2010.12.003.

引用本文的文献

Metabolic assessment of cerebral palsy with normal clinical MRI using F-FDG PET imaging: A preliminary report.

Front Neurol. 2022 Sep 15;13:844911. doi: 10.3389/fneur.2022.844911. eCollection 2022.

Clinical Relevance of [F]Florbetaben and [F]FDG PET/CT Imaging on the Management of Patients with Dementia.

Molecules. 2021 Feb 26;26(5):1282. doi: 10.3390/molecules26051282.

Recent Advances in Zirconium-89 Chelator Development.

Molecules. 2018 Mar 12;23(3):638. doi: 10.3390/molecules23030638.

Glucose metabolism measured by positron emission tomography is reduced in patients with white matter presumably ischemic lesions.

Med Sci Monit. 2014 Aug 27;20:1525-30. doi: 10.12659/MSM.892137.

Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis.

PLoS One. 2013 Jul 23;8(7):e69190. doi: 10.1371/journal.pone.0069190. Print 2013.

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Alzheimers Dement. 2013 Jan;9(1):e-1-16. doi: 10.1016/j.jalz.2013.01.002.